Abstract Details

Title Patient Demographics and Health Plan Paid Costs in CIDP

Topic Peripheral Nerve

Presentation(s) (-)

Poster/Presentation
Number 007

Objective

Background Little is known about health care resource use or the costs of managing CIDP in the US.

Design/Methods Patients with CIDP from the Accordant Health Services (AHS) medical and pharmacy claims database in 2011 were identified. Data were analyzed from nine specific US commercial health plans. To improve the diagnostic certainty of CIDP, only patients eligible for the AHS CIDP care management program were included in the analysis. The CIDP diagnosis was confirmed by an algorithm that included ICD9 diagnosis codes, pharmacy utilization, and, when necessary, medical review by AHS staff. Analyzed data included demographics, the prevalence of specified comorbidities, and mean health plan paid cost per member per year (PMPY). Prescribed drug classes, drug names, and place of service for health care claims were also identified.

Results From 6.5 million covered health plan lives, 73 (56% males; mean age 47) met the study entry criteria. The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%). Therapeutic plasma exchange (3%) and nonsteroidal immunosuppressives (7%) were used rarely. Mean health plan paid costs PMPY were $56,953. Pharmacy costs comprised 57% of the total paid amount and were the major cost driver. IVIg comprised 90% of the total pharmacy costs for CIDP patients.

Conclusions Annual health care costs for CIDP are substantial with a large cost burden in pharmacy utilization. IVIg (FDA approved for CIDP) is the primary cost driver. With the emphasis on the rational use of health care resources, studies are needed to determine optimal long-term treatment strategies for CIDP, particularly with regard to IVIg.

Authors/Disclosures
Jeff Guptill, MD, FAAN (argenx US) PRESENTER	Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx.
	No disclosure on file
Mark B. Bromberg, MD, PhD, FAAN (University of Utah)	Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health. Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Bromberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx. Dr. Bromberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Grifols. Dr. Bromberg has received publishing royalties from a publication relating to health care. Dr. Bromberg has received publishing royalties from a publication relating to health care. Dr. Bromberg has received publishing royalties from a publication relating to health care. Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving as a Medical reviewer with Department of Justice, Vaccination Compensation Board.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Donald B. Sanders, MD, FAAN (Duke University Medical Center)	Dr. Sanders has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant Health Services. Dr. Sanders has received personal compensation in the range of $0-$499 for serving as a Consultant for Cabaletta BIO. Dr. Sanders has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kashiv Biosciences. Dr. Sanders has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta Pharmaceuticals. Dr. Sanders has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen RnD. Dr. Sanders has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-aventis. Dr. Sanders has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VielaBio. Dr. Sanders has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��